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Reversible acetylation of histone and non-
histone proteins plays pivotal role in cellular ho-
meostasis. Dysfunction of histone acetyltrans-
ferases (HATs) leads to several diseases
including cancer, neurodegenaration, asthma,
diabetes, AIDS, and cardiac hypertrophy. We
describe the synthesis and characterization of
a set of p300-HAT-specific small-molecule
inhibitors from a natural nonspecific HAT in-
hibitor, garcinol, which is highly toxic to cells.
We show that the specific inhibitor selectively
represses the p300-mediated acetylation of p53
in vivo. Furthermore, inhibition of p300-HAT
down regulates several genes but significantly
a few important genes are also upregulated.
Remarkably, these inhibitors were found to be
nontoxic to T cells, inhibit histone acetylation
of HIV infected cells, and consequently inhibit
the multiplication of HIV.
INTRODUCTION
Eukaryotic genome is organized in a highly complex
nucleoprotein structure, chromatin. Physiologically chro-
matin is not just DNA and histone complex but rather is
a dynamic organization of DNA associated with histone
and histone-interacting nonhistone proteins [1]. The hall-
mark of chromatin is its dynamic nature, which is essential
for the regulation of nuclear processes that require access
to the genetic information. Several strategies exist to alter
the dynamic properties of chromatin including posttrans-
lational modifications of histone and nonhistone chroma-
tin components. Among the different posttranslational
modifications, reversible acetylation of histones and dif-
ferent nonhistone nuclear proteins play a significant roleChemistry & Biology 14, 6tomaintain the nuclear functions. Two groups of enzymes,
namely, histone acetyltransferases (HATs) and deacety-
lases (HDACs), balance the acetylation level as required
for cellular function [2]. Based on the protein homology,
substrate specificity, and functional consequences,
nuclear HATs can be broadly classified under different
heads: (1) p300/CBP family; (2) MYST family that consists
of Sas2, Sas3, Esa1, MOF, Tip60, MOZ, MORF, HBO1;
(3) the GNAT superfamily that includes Hat1, Gcn5,
PCAF, Elp3, Hpa2; (4) Nuclear receptor coactivators like
SRC-1, ACTR, TIF2; (5) TAFII250 family; and (6) TFIIIC
family [3].
p300 and its close homolog CBP are probably the most
widely studied histone acetyltransferases. It has been
implicated in a number of diverse biological functions
such as proliferation, cell-cycle regulation, apoptosis,
differentiation, and DNA damage response [4, 5]. It is a
potent transcriptional coactivator, which interacts with
constantly expanding array of transcription factors [6, 7].
Both p300 and CBP have been found to possess intrinsic
HAT activity [8, 9]. Unlike, most of the other HATs that
have limited substrate specificity for histone and nonhis-
tone proteins, p300 and CBP are capable of acetylating
all the four core histones and also a wide variety of nonhis-
tone proteins with functional consequences in several
cases [10]. p300 is a multifunctional protein and all the
functions are not HAT activity dependent. However,
several important cellular functions are regulated by
p300-mediated protein (both histone and nonhistone)
acetylation including DNA repair, cell cycle, differentiation,
and establishment of retroviral pathogenesis [11, 12].
Lysine-specific acetylation of histone H3 and H4 by
p300 in conjunction with chromatin remodeling and other
covalent modifications establishes the active state of
a chromatin in a gene-specific manner [13]. p300-medi-
ated acetylation of nucleosome-1 (nuc-1) in the integrated
HIV genome is essential for the viral gene expression.
Furthermore, acetylation of Tat and HIV-1 integrase were
also found to be indispensable for the establishment of45–657, June 2007 ª2007 Elsevier Ltd All rights reserved 645
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p300-Specific HAT Inhibitorviral pathogenesis [14, 15]. Apart from Tat or Integrase,
there are several nonhistone nuclear proteins that get
acetylated by p300, and as result of which, the functional
properties of these proteins are altered. The tumor
suppressor p53 gets acetylated by p300 at K373/K382
and by PCAF at K320 residues. The lysine acetylation at
these sites of p53 is linked to its ability to regulate cell
cycle and apoptosis [16]. In response to DNA damage,
N terminus of p53 first becomes phosphorylated at serine
33 and 37, and as a consequence, phosphorylated p53
activates p300 and PCAF to induce p53 acetylation at
K373/382 and K320, respectively [17]. However, though
acetylation of histone and nonhistone proteins is predom-
inantly associated with transcriptional activation, it is not
exclusive. It is evident that p300 acetyltransferase activity
is essential for transcriptional repression by promyelocytic
leukemia zinc finger (PLZF) protein and HDAC1 [18, 19]
(see Discussion).
Because of its involvement in these important cellular
events, dysfunction of p300may be the underlying causes
of several diseases, including a few types of cancers, car-
diac hypertrophy, asthma, and diabetes [4, 20, 21]. HAT
activity of p300 therefore is being considered as a target
for the new generation therapeutics. Unlike histone de-
acetylase inhibitors, the number of HAT modulators (acti-
vator and inhibitors) discovered so far is scanty. Among
the synthetic HAT modulators, the first group to be de-
scribed was the Peptide Co-A conjugates, of these Lys
Co-A was specific for p300, and H3 Co-A20 was specific
for PCAF [22]. Furthermore, g-butyrolactones were found
as first-known small-molecule inhibitors of human Gcn5
HAT activity [23]. Recently, isothiazolones-based modula-
tors have also been designed that inhibits both p300 and
PCAF [24]. The search for specific natural small-molecule
modulators of HATs succeeded when anacardic acid
from cashew nut-shell liquid was found as a potent inhib-
itor of p300 and PCAF. Furthermore, CTPB (N-[4-chloro-
3-trifluoromethyl-phenyl]-2-ethoxy-6-pentadecyl-benza-
mide), an amide derived by using anacardic acid as a
synthon, remarkably activates p300 HAT activity. Unfortu-
nately, these compounds were found to have poor cell-
membrane-permeability potential [25]. The lead develop-
ment in the field was initiated when another natural
small-molecule inhibitor of HATs, garcinol, a polyisopreny-
lated benzophenone derivative from Garcinia indica fruit
rind was discovered [26]. Garcinol was found to be a
nonspecific HAT inhibitor (HATi) but highly permeable to
cultured cells and a potent inhibitor of histone acetylation
in vivo. The nonspecific nature of garcinol made it highly
cytotoxic. Therefore, the potential use of garcinol to target
p300 for understanding the physiological role of HATs or
to develop a therapeutic molecule is less likely. These
limitations of garcinol inspired us to synthesize several
derivatives of this potent inhibitor to find out specific and
less toxic HAT inhibitors. Among nearly 50 derivatives
synthesized from garcinol, three were found to be highly
specific for HAT activity of p300. The p300 selectivity
was established in vivo by site-specific inhibition of p53
acetylation by one of the inhibitor, LTK-14. The highly646 Chemistry & Biology 14, 645–657, June 2007 ª2007 Elsevieselective nature of LTK-14 prompted us to investigate
the role of p300-HAT activity in the regulation of global
gene expression. Furthermore, the specific inhibitor was
found not only to be nontoxic to T cells but also repressed
the HIV replication in these cells. The selective p300 inhib-
itor thus could be useful as a biological switchingmolecule
for probing the role of p300-HAT in cellular physiology and
may also serve as a lead compound to develop new gen-
eration therapeutics.
RESULTS
Isogarcinol Derivatives Are Specific Inhibitors
of Histone Acetyltransferase p300
The polyisoprenylated benzophenone garcinol isolated
from Garcinia indica fruit rind was found to be a highly
cytotoxic and a nonspecific inhibitor of HATs. In order to
find out more potent, specific, and less toxic inhibitors,
we synthesized and characterized several derivatives of
isogarcinol (IG), a product of intramolecular cyclization
of garcinol (Scheme S1 available with this article online).
IG was subjected to controlled modification and mono-
substitution at ‘‘14’’ position to synthesize 14-isopropoxy
IG (LTK-13) and 14-methoxy IG (LTK-14). The disubstitu-
tion of IG generated 13, 14 diisopropoxy IG (LTK-13A); 13,
14 dimethoxy IG (LTK-14A); 13, 14 diacetoxy IG (LTK-
15); and 13, 14 disulfoxy IG (LTK-19). It was found that
the mono substituted IG derivatives LTK-13, -14, and
disubstituted LTK-19 could inhibit the p300-HAT activity
but not the PCAF-HAT activity (Figure 1A, lanes 5, 6, and
8), although the parent compound IG inhibits HAT activi-
ties of both p300 and PCAF nonspecifically (Figure 1A,
lane 4). Interestingly, one of the derivatives, LTK-15,
almost lost the HAT inhibition activity; it could inhibit the
p300-mediated acetylation less than 10% and has no
effect on PCAF-HAT activity (Figure 1A, lane 7). Further-
more, the other disubstituted IG derivatives, LTK-13 A
and LTK-14 A, also completely lost their activity (data
not shown). The IC50 of LTK-13, -14, and -19 to p300-
HAT activity were found to be 5–7 mM, which is similar to
IG. In order to visualize the inhibition pattern of histone
acetylation, HAT assay products were analyzed by fluo-
rography followed by autoradiography. In agreement
with filter-binding data, it was found that in the presence
of 10 mMof LTK-13, -14, and -19, p300-mediated acetyla-
tion of histones H3 and H4 were equally inhibited up to
85%–90% as compared to DMSO solvent control (com-
pare Figure 1B lanes 5, 6, and 8 with lane 3); histone acet-
ylation by PCAF (predominantly at histone H3) was not
affected by LTK-13, -14, and -19 (Figure 1C, lanes 5, 6,
and 8). As expected, the presence of 10 mM concentration
of IG, however, efficiently inhibited histone acetylation by
both p300 and PCAF (Figures 1B and 1C, compare lane
3 with 4). However, dose-dependent inhibition of p300-
HAT activity was also observed in the presence of LTK-
14. Significantly, HAT-activity of PCAF remained un-
change even in the presence of 50 mM of LTK14
(Figure S1). In order to ensure the selectivity for p300-
HAT activity, we went ahead to check the effect of IGr Ltd All rights reserved
Chemistry & Biology
p300-Specific HAT Inhibitorderivatives on the HAT activity of hGcn5, histone deacety-
lase, HDAC1; arginine methyltransferase, CARM1; and
lysine methyltransferase, G9a. Significantly, these
chromatin modifying enzyme activities were not affected
by the presence of IG and its derivatives LTK-13, -14,
and -19 (Figure S2). Taken together, these data suggests
that the IG derivatives are specific inhibitors of p300-HAT
activity.
Figure 1. Isogarcinol Derivatives Are Specific Inhibitors of
p300-HAT
HAT assays were performed either with p300 or PCAF in the presence
and absence of IG or its derivatives by using highly purified HeLa core
histones and processed for filter binding (A) or fluorography (B and C).
Lane 1, core histones without HAT; lane 2, histones with HAT; lane 3,
histones with HAT and in the presence of DMSO; lanes 4–8, histones
with HAT and in the presence of IG or its derivatives LTK-13, -14,
-15, and -19. Error bars are standard deviation of mean of at least three
replicates.Chemistry & Biology 14, 6p300-Specific Inhibitors Induce Specific Alteration
in the Enzyme Conformation as Revealed by
Surfaced-Enhanced Raman Spectroscopy
We were further interested to find out whether derivatiza-
tion of nonspecific compounds alters its functional inter-
action with the enzyme p300 and also the downstream
consequences. Addition of noble metal nanoparticles to
biological or chemical molecules produces an enhance-
ment in their Raman intensities and this technique is
popularly known as surface-enhanced Raman spectros-
copy (SERS). To address this mechanistic aspect, the
complex of the compound and the p300 were subjected
to SERS investigation. The detailed SERS analysis of
p300 molecule has been reported earlier [27]. Figure 2
shows the SERS spectra of p300 and p300 complexes
with garcinol, IG, and IG derivatives. The p300 spectrum,
as reported earlier, is dominated with the Raman features
associated with ring-structured amino acids tryptophan
(Trp), tyrosine (Tyr), phenylalanine (Phe), and histidine
(His) [27]. p300 is known to contain several units of Trp,
Tyr, Phe, and His in it. The spectrum of p300 is also having
a prominent Amide I band around 1624 cm1 and 1656
cm1 associated with the a-helix structure. The spectrum
of p300 with and without DMSO were found to be quite
similar (Figures 2A and 2B), suggesting that there is no
contribution from the DMSO to the SERS spectrum of
p300. The aromatic ligands, such as garcinol and IG,
would form hydrogen bonds and/or have hydrophobic
interactions with the protein resulting in the change of
the structure of the protein. Since Raman spectrum is
closely related to the structure, we expect the changes
in Raman spectra upon formation of these complexes.
However, there is a small difference in the chemical struc-
tures of garcinol and IG molecules, namely, the presence
of a hydroxyl group in the garcinol instead of the oxygen
bridging in IG as shown in Table 1. Raman spectra of
p300 in the presence of these molecules are shown in Fig-
ures 2C and 2D. The Raman spectrum of p300 bound with
garcinol shows changes mostly to the amide bands of the
a-helix, like 1624 cm1 and 1296 cm1, carboxylic group
vibrations of the alphatic amino acids (985 cm1 and
684 cm1), and certain Tyr modes, like 803 cm1. On
the other hand, IG causes a large-scale change to the
p300 spectra. Along with the modes affected in the case
of garcinol, the binding of IG also affects all the modes
related to Tyr, Trp, Phe, and His. Next, we looked at the
derivatives of IG, namely LTK-13, -14, -15, and -19. The
Figure 2 shows the SERS spectra of p300 complexes
with (Figure 2E) LTK-13, (Figure 2F) LTK-14, (Figure 2G)
LTK-19, and (Figure 2H) LTK-15. It is important to note
that upon addition of LTK-15, the inactive IG derivative,
there is no change to the SERS spectra of p300
(Figure 2H). In the case of LTK-13, the change in the
p300 spectra is limited to the amide bands of the a-helix
(1656 cm1 and 1517 cm1) and certain carboxylic groups
of the alphatic amino acids (737 cm1 and 617 cm1). On
the other hand, both LTK-14 and -19 causes large-scale
changes in the p300 spectra. Like in the case of IG, bind-
ing of both LTK-14 and -19 affects not only the amide45–657, June 2007 ª2007 Elsevier Ltd All rights reserved 647
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p300-Specific HAT InhibitorFigure 2. SERS Studies of p300 and
Compound Interaction
SERS spectra of (A) p300, (B) p300 + DMSO,
(C) p300 + Garcinol, (D) p300 + Isogarcinol,
(E) p300 + LTK-13, (F) p300 + LTK-14, (G)
p300 + LTK-19, and (H) p300 + LTK-15. Laser
excitation, 632.81 nm; laser power at the
sample, 8 mW; accumulation time, 180 s.modes but also all the modes related to Trp, Tyr, Phe,
and His. Unlike in the case of IG, in both LTK-14 and
-19, the carboxylic side group of the aliphatic amino acid
is unaffected, namely, 621 cm1 (compare Figure 2D
with Figure 2F and 2G). Taken together, these data sug-
gest that the specific and nonspecific inhibitors of p300
bind to the amide groups of a helix and thereby differen-
tially alter the enzyme structure.
Isogarcinol Derivatives Inhibit the Histone
Acetylation In Vivo in HeLa Cells
The next question we asked is whether these molecules
inhibit the histone acetylation in vivo. In order to investi-
gate the effect of these compounds on the acetylation of
histones in vivo, HeLa cells were treated with IG or its
derivatives at a concentration of 100 mM for 24 hr. His-
tones were isolated from control and compound-treated
cells and subjected to western blotting analysis with anti-
acetyl histone H3 and histone H3 antibodies. Under these
experimental conditions, acetylation of histone H3 in
untreated as well as DMSO-treated cells could not be
detected (Figure 3A, lanes 1 and 2). Therefore, histone
acetylation was induced by treating the cells with histone
deacetylase inhibitors (NaBu and TSA) (Figure 3A, lanes
3 to 7). In the presence of these inhibitors, cells were
treated with IG and its derivatives (100 mM). The results
show 70% to 80% inhibition of total acetylation of histones
in the case of cells treated with LTK-13, -14, and -19
(Figure 3A, compare lanes 5, 6, and 7 with 3), whereas
cells treated with IG show near complete inhibition of total
histone acetylation (Figure 3A, compare lane 4 with 3). To
visualize the inhibition pattern of histone acetylation in the
cells, immunofluroscence studies were carried out by
using antiacetyl histone H3 antibodies. Distinct pattern
of histone acetylation inhibition was found in the case of
cells treated with LTK-14, one of the p300 specific HATi as
compared to DMSO (Figure 3B, lane 1, panel I versus II).648 Chemistry & Biology 14, 645–657, June 2007 ª2007 ElsevierHoechst staining has been shown as control for visual-
izing nucleus (Figure 3B, lane 2). Merge image shows the
distinct inhibition pattern of histone H3 acetylation in vivo
upon LTK-14 treatment (Figure 3B, lane 3, panel I versus
II). The intensity of the color was quantified and plotted
against the length of the image (Figure 3B, lane 4) with
a Zeiss LSM.5 Image Examiner. The graphs depict a sig-
nificant decrease in the histone acetylation (green line)
in case of cells treated with LTK-14 as compared to
DMSO-treated cells (Figure 3B, lane 4, compare panel I
versus II). The blue line represents the nuclei stained with
Hoechst. In agreement with western blotting analysis,
these data suggest that cells are permeable to these inhib-
itors and inhibit histone acetylation in vivo.
LTK-14 Inhibits the p300-, but Not PCAF-, Mediated
Acetylation of p53
Although in vivo histone acetylation (inhibition) pattern
upon treatment with specific inhibitor suggests that the
compounds target HAT activity in the cell, the data do
not establish the in vivo specificity. To test the specificity
of p300-mediated acetylation, we selected p53 as a
substrate, which gets acetylated at specific sites by
p300 and PCAF very distinctly upon DNA damage. The
effect of LTK-14 (Figures 4A and 4B) on acetylation of
p53 in vitro was tested by using either p300 or PCAF
and bacterially expressed Flag-p53 as substrate. Remark-
ably, it was observed that LTK-14 inhibited the acetylation
of p53 by p300 at 25 mM concentration as compared to
DMSO (Figure 4C, compare lane 3 with 4), but the pres-
ence of the inhibitor does not affect the p53 acetylation
by PCAF (Figure 4C, compare lane 6 with 7). These results
suggest that acetylation of p53 by p300 is significantly
knocked down in the presence of LTK-14. We further
addressed the nature of inhibition in vivo. For this purpose,
wild-type p53 expressing A549 human lung carcinoma
cells were selected. Cells were treated with the compoundLtd All rights reserved
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p300-Specific HAT InhibitorTable 1. Activities and IC50 of HAT Inhibitors

































5–7 mM Nontoxicfor 24 hr following which expression of p53 was enhanced
upon treatment with doxorubicin at different time points, 6
and 12 hr. Whole-cell extract was prepared from the cells
and subjected to western blotting analysis with antibodies
against p53, acetyl p53 (K373), acetyl p53 (K320), and
a actin. It was found that at both time points (6 and
12 hr), acetylation of p53 at lysine 373 (by p300) was in-
hibited by the treatment with LTK-14 (Figure 4D, panel I,
lane 1 versus 3 and lane 2 versus 4). Significantly, the
specific inhibitor did not affect the acetylation at the lysine
320 (by PCAF) (Figure 4D, panel II, lanes 1 versus 3 and
lanes 2 versus 4), whereas presence of IG inhibited the
acetylation of p53 at both p300 and PCAF specific sites
(Figure S3). Taken together, these results suggest that
indeed the inhibitor (LTK-14) obtained by derivatization
of IG specifically targets p300 in vivo.
LTK-14 Inhibits p300-HAT Activity-Dependent
Chromatin Transcription and Alters Global
Gene Expression
In order to find out the effect of p300 specificity of IG
derivatives on gene expression, we used the p300-HATChemistry & Biology 14, 6activity-dependent in vitro reconstituted chromatin
transcription assay system as described previously [22].
The transcription assay followed the protocol depicted in
Figure 5A. Addition of 50 mM concentration of LTK-14
does not show any effect on activator dependent DNA
transcription (Figure 5B, lane 6). Even the presence of
DMSO, 50 mM concentrations of garcinol and IG did not
show any effect on transcription from DNA template
(Figure 5B, lanes 3, 4, and 5). The activator-independent
transcription fromML 200 promoter was used as a loading
control. In this assay system, transcription from the chro-
matin template is dependent on p300-mediated acetyla-
tion of promoter proximal core histones (Figure 5C, lane
3 versus 4) [6]. Addition of DMSO marginally enhances
the transcription from the chromatin template (Figure 5C,
lane 4 versus 5). However, the presence of 50 mMconcen-
tration of LTK-14 shows 70% to 80% inhibition of tran-
scription from chromatin template (Figure 5C, compare
lane 5 with 8). Presence of similar concentrations of non-
specific HAT inhibitors, garcinol and IG, show near com-
plete inhibition of transcription (Figure 5C, compare lane
5 with 6 and 7). This could be because garcinol and IG45–657, June 2007 ª2007 Elsevier Ltd All rights reserved 649
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p300-Specific HAT InhibitorFigure 3. Isogarcinol Derivatives Inhibit Histone Acetylation In Vivo in HeLa Cells
(A) HeLa cells were treated as indicated for 24 hr; lane 1, histones extracted from untreated cells; lane 2, DMSO treated cells; lane 3, NaBu- (1mM) and
TSA- (2 mM) treated cells; lane 4, NaBu- (1 mM), TSA- (2 mM) and IG-treated cells; lanes 5, 6, and 7, cells treated with NaBu (1 mM) and TSA (2 mM) and
LTK-13, -14, or -19 respectively. The acid extracted histones were resolved over 12% SDS-PAGE and subjected to western analysis with antibodies
against acetylated histone H3.
(B) Inhibition of histone acetylation in HeLa cells by LTK-14 was visualized by immunofluroscence with antiacetyl histone H3 antibodies. Panel I
represents cells treated with DMSO, and panel II represents cells treated with LTK-14 (100 mM). Lane 1, stained with acetyl histone H3 antibody;
lane 2, cells stained with Hoechst; lane 3, merge image of lanes 1 and 2; lane 4, quantitative representation of lanes 1 and 2.inhibit all theHATspresent in the nuclear extract in addition
to p300, but LTK-14 inhibits only p300 but not the other
HATs present in the nuclear extract. However, inhibition
of p300-HAT activity-dependent chromatin transcription
by LTK-14 encouraged us to investigate the effect of
p300 inhibition on the global gene expression. For this pur-
pose, HeLa cells were treatedwith 100 mMLTK-14 for 24 hr
and subjected to microarray analysis. Genome-wide anal-
ysis of gene expression indicated that a large number of
genes were downregulated (118 genes). Remarkably,
a few genes were also upregulated upon the inhibition of
p300-HAT activity (see Discussion). We have clustered
genes according to the level of expression (Figure 5D). An
extensive table with all the differentially expressed genes
tabulated is available (Table S1). The results were further
validated by real-time PCR analysis (Figure 5E).
LTK-14 Inhibits HIV Multiplication in T Cells
Garcinol and IG were found to be highly toxic, presumably
because of their nonspecific nature. Importantly, we found
that the specific derivatives are significantly less toxic to650 Chemistry & Biology 14, 645–657, June 2007 ª2007 ElsevierHeLa cells as compared to the parent compounds
(Figure S4). Furthermore, these derivatives were also
found to be nontoxic to T cells up to 50 mM concentration
(Figure 6A). These results prompted us to test the p300
specific, nontoxic derivatives on HIV multiplication in
T cells. We tested the effect of specific derivative, LTK-
14 on virus syncytia formation upon infection on SupT1
cells. SupT1 cells are highly permeable for HIV-1, and
these cells make numerous and large syncytia when
infected with the virus. Taking advantage of this property,
we cocultured SupT1 cells in the presence of H9/HTLV-
IIIb NIH 1983 cells that produce a T cell tropic virus. A
dose-dependent reduction in the number of syncytia as
well as the production of HIV core protein p24 was evident
with increasing concentration of LTK-14 (Figures 6B–6D).
The difference between treated cells with control was
statistically significant at all the time points as evaluated
by Student’s paired t test (p < 0.005). However, LTK-14
could inhibit the acetylation of histones in T cells sig-
nificantly (Figure 6E, compare lanes 1, 2, and 3 with 4–12).
These results show that the p300-specific HAT inhibitorLtd All rights reserved
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p300-Specific HAT InhibitorFigure 4. LTK-14 Specifically Inhibits p300-Mediated Acetylation of p53
X-ray crystal structure of LTK-14. (A) Ball-and-stick representation generated by Pymol (hydrogen atoms are not shown for clarity). (B) ORTEP
diagrams showing the displacement Ellipsoids are at the 10% probability level. Color coding of the atoms; green represents carbon atoms, and
red represents oxygen. (C) In vitro acetyltransferase assays were performed either with p300 or PCAF in the presence or absence of LTK-14 by using
Flag-tagged p53 as a substrate. Lane 1, p53 without enzymes; lane 2, p53 in the presence of p300: lane 3, p53 with p300 in the presence of DMSO;
lane 4, p53 with p300 in the presence of LTK-14; lane 5, p53 with PCAF; lane 6, p53 with PCAF in the presence of DMSO; lane 7, p53 with PCAF in the
presence of LTK-14. Bottom panel represents Coomassie-stained proteins as loading control. (D) A549 cells were treated with either DMSO or
LTK-14 for 24 hr. Cells were then incubated with doxorubicin. Lanes 1 and 2, cells treated with DMSO, and lanes 3 and 4, cells with LTK-14, followed
by doxorubicin for indicated time points. The cell lysates from the above treatments were probed with a anti acetyl p53 K373 (panel I) and anti acetyl
p53 K320 (panel II), anti p53 DO-1 (panel III) and anti actin (panel IV).Chemistry & Biology 14, 645–657, June 2007 ª2007 Elsevier Ltd All rights reserved 651
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p300-Specific HAT InhibitorFigure 5. LTK-14 Inhibits the p300-HAT Activity-Dependent Chromatin Transcription In Vitro and Alters Global Gene Expression in
HeLa Cells
Schematic representation of the in vitro transcription protocol (A), in vitro transcription from naked DNA (B), and chromatin template (C). Thirty nano-
grams of DNA and freshly assembled chromatin template (equal amount of 30 ng of DNA) were subjected to protocol (A) with or without HATi. (D)
Microarray analysis of gene expression upon treatment of HeLa cells with p300-specific inhibitor LTK-14. Hierarchical clustering of gene expression
profile data obtained by cDNA microarray analysis upon inhibition of p300-HAT. Lanes 1 and 2 represents forward reaction, and 3 and 4 represent
dye swap. (E) Validation of differentially altered genes by using real-time PCR: PLIN represents upregulated gene, and ATF6 downregulated gene.




p300-Specific HAT InhibitorFigure 6. Nontoxic p300-Specific Inhibitor LTK-14 Represses HIV Multiplication through the Inhibition of Histone Acetylation in
T Cells
(A) Trypan blue cell viability assay was carried out to determine the toxicity of LTK-14 to T cells. Lane 1, DMSO treated cells; lanes 2, 3, and 4, treated
with LTK-14, at 10, 25, and 50 mMconcentrations, respectively. Three individual experiments were carried out, and percent cell death was calculated
and plotted against each treatment.
(B) LTK-14 was added to the wells to the final concentration as shown, and the cultures were incubated at 37C. Formation of syncytia is visible unde
light microscope within 12 hr.
(C) The total number of syncytia in ten representativewellswas counted and presented. The data are representative of three independent experiments
(D) The viral structural protein, p24, secreted into the culture medium was estimated by using an antigen-capture assay. The difference between cells
treated with control and 50 mM concentration was found to be statistically significant by Student’s paired t test. Error bars are standard deviation o
mean of at least three replicates.
(E) Inhibition of histone acetylation in the infected T cells was visualized by western blotting with antiacetylated histone H3 antibodies. Cells were
treated with 10, 25, and 50 mM concentration of compound for 24, 48, and 72 hr as indicated. Histones isolated from the above treatments were
subjected to western blotting.LTK-14 inhibits the multiplication of HIV at least partially,
through the inhibition of acetylation of histones.
DISCUSSION
Though the existence of HATs has been known for
nearly 40 years, the recombinant HATs, initially Gcn5Chemistry & Biology 14, 6and then p300/CBP were discovered only a decade ago.
Availability of the recombinant enzymes enabled the
synthesis of the HAT-specific modulators, especially
inhibitors [22]. However, it was challenging to find out
the natural molecules, which have the HAT-modulating
activity. The first known cell-permeable small-molecule
HAT inhibitor is garcinol, an isoprenylated benzophenone45–657, June 2007 ª2007 Elsevier Ltd All rights reserved 653
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p300-Specific HAT Inhibitorderivative isolated from Garcinia indica fruit rind. Garcinol
was found to be highly potent nonspecific HAT inhibitor,
which inhibits histone acetylation in vivo and induces
apoptosis [26]. These results are in agreement with the
notion that natural products often demonstrate nonselec-
tive and broad-range activity against several classes of
enzymes with high affinity; therefore, they are likely to
be cytotoxic to mammalian cells. This phenomenon pro-
vides an opportunity for chemical biologists to synthesize
selective, more potent, and less toxic analogs by small
modifications of natural products. In the present report,
we synthesized several derivatives of garcinol, to achieve
selective inhibition of HAT activity. Upon intramolecular
cyclization of garcinol, another nonspecific inhibitor IG
was synthesized. Initially, we aimed at synthesizing
p300/CBP-specific inhibitor. Nonavailability of the 3D
structure of the enzyme was limiting factor for synthesis
of structure-based ligands. However, monosubstitution
or disubstitution by electron donor or electron withdraw-
ing functional groups at 14 and/or 13 oxygen atoms was
considered as a potential strategy for synthesizing differ-
ent IG derivatives. Significantly, out of several derivatives
synthesized, three (LTK-13, -14, and -19) showed exclu-
sive specificity for p300-HAT activity. With the exception
of the sulphonyl group disubstitution, all the other
disubstitutions would fail to confer the specificity to the
derivatives. For example, disubstitution by acetyl moiety
resulted in a loss of activity (LTK-15). Molecular interac-
tions of p300 with different derivatives was investigated
by using surface-enhanced Raman spectroscopy studies,
which clearly showed that the mode of interaction and
consequent alteration of enzyme structure of specific
versus nonspecific inhibitors differ significantly (Figure 2).
Furthermore, the inactive inhibitor seems to have lost the
ability to interact with the enzymes (Figure 2H). LTK14
could not affect the autoacetylation of p300, within
the concentration range of the HAT inhibition (data not
shown). The kinetics data suggests that the specific
inhibitor (LTK-14) mediated inhibition pattern is signifi-
cantly different from the nonspecific parent compound.
It is a mixed type for both histones as well as acetyl
Co-A, whereas garcinol was found to be a competitive
for histones and mixed type for acetyl Co-A (Figure S5).
Presumably, the inhibitor binds to specific pocket of the
enzyme other than the active site. Therefore, specific
alteration of enzyme structure by the derivatives might
have lead to the selective inhibition of p300-HAT activity.
The p300-mediated acetylation regulates the tumor
suppressor functions not only through the acetylation of
histones but also through the acetylation of p53. Role of
p53 acetylation in cellular gate-keeping functions is
controversial [16, 28]; however, the significant implication
of it is beyond doubt. p53 gets reversibly acetylated at C
terminus by p300 and PCAF in a site-specific manner.
Functional significance of each of these site-specific
acetylations is yet to be established in the context of
p53-mediated cell-cycle arrest or apoptosis. We found
that LTK-14 remarkably inhibits only p300-mediated p53
acetylation in vitro as well as in vivo (Figures 4C and 4D).654 Chemistry & Biology 14, 645–657, June 2007 ª2007 ElseviThese data establish that LTK-14 is indeed a p300-
specific inhibitor.
Through its intrinsic HAT activity, p300 play significant
role in the transcriptional activation from the chromatin,
which is the major molecular basis for its function [6].
Having recruited by the transcriptional activator, p300
acetylates the promoter proximal histones and thereby
facilitates transcription initiation. We found that LTK-14
inhibits the acetylation-dependent (by p300) chromatin
transcription in vitro (Figure 5C). Microarray analysis of
the p300 selective inhibitor (LTK-14)-treated cells resulted
in a large number (118) of downregulated genes. Signifi-
cantly, a few (six) important genes were also upregulated
(Figure 5D). Among the downregulated genes, many are
involved in different cellular functions such as cell cycle
(HSP90B1) [29], differentiation (CAST [30]), proliferation
(BECN1 [31]), and apoptosis (ATF6 [32]). These results
may be useful to identify the molecular target of p300 for
cell growth, differentiation, and death. A few downregu-
lated genes such as MAPK8IP1 (mitogen-activated
protein kinase 8-interacting protein 1) and HSP90B1 are
signal sensors involved in key cellular signaling processes
[33, 34]. Interestingly, couple of oncogenes such as,
MYC [35],V-Yes-1 [36], andRAS25 (RASoncogene homo-
log) [37] were downregulated. Furthermore, many genes
involved indiseases likediabetes (MAPK8IP1 [38]), asthma
(HSPG2 [Perlecan] [39]), heart andcardiomyopathy (MYO6
[40]), and cancer (DIABLO [41]) were downregulated.
These results further establish that p300 is indeedamolec-
ular target for many diseases. Among the upregulated
genes, few are involved in cell growth and differentiation
(GLDN [42]), metabolism (PLIN [43]), and cell signaling
(PLIN [43]). Interestingly, the upregulated gene PLIN is
involved in diabetes and obesity-related disorders [44].
Several genes with unknown function were altered upon
p300 inhibition; analysis of these genes would be helpful
to assign new roles for p300/CBP (Table S1), and such
analysis would be helpful in unraveling the diverse but
uncharacterized mechanisms of p300 either in gene acti-
vation or repression, ultimately leading to pathogenesis.
Derivatization of IG toward the more selective inhibitory
function made these molecules significantly nontoxic to
HeLa cells (Figure S4) as revealed by Tryphan blue cell
viability assay. Toxicity of these molecules has been con-
siderably reduced also for T cells (Figure 6A) and embry-
onic stem cells (data not shown). Since p300 mediated
acetylation of different HIV proteins (Tat, integrase) as
well as nucleosomes on the integrated HIV genome is
essential for the multiplication of HIV, we tested the effect
of LTK-14 on the viral gene expression. The results
demonstrate that viral syncitia formation reduced signifi-
cantly in the presence of the p300-specific HAT inhibitor
(LTK-14) within its nontoxic range of concentration. The
inhibition of HIV multiplication was further confirmed by
the estimation of viral coat protein p24 production, and
the results were found to be statistically significant. Inhibi-
tion of HIVmultiplication is in agreement with the inhibition
of histone acetylation in T cells (Figure 6E). p300-mediated
acetylation of HIV-1 integrase is indispensable for theer Ltd All rights reserved
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Therefore, we presume that inhibition of syncitia formation
by the presence of p300-specific inhibitor could also be
through the inhibition of acetylation of integrase and its
downstream activity that further stops the spread of the
infection. The p300-specific inhibitors may act at different
stages of HIV life cycle starting from its integration into
human genome to gene expression after integration. How-
ever, in vivo acetylation status of Tat and HIV-1 integrase
could not be tested upon compound treatment because of
the limited amount of proteins synthesized in the infected
cells.
SIGNIFICANCE
p300 plays a critical role in cell growth, differentiation,
and death. Several of these functions require intrinsic
HAT activity of p300-HAT. Because of its critical role in
diverse cellular functions, dysfunction of p300 may be
the underlying cause of many diseases including
cancer. p300 also plays a crucial role in the establish-
ment of HIV pathogenesis. However, the molecular
basis of p300 contribution toward diverse cellular
processes is still unresolved. We have synthesized
a few cell-permeable, p300-HAT-specific inhibitors
fromnonspecific andhighly toxic naturalHAT inhibitor,
garcinol. These specific and nontoxic small molecules
would be highly useful to understand the biological
roles of HAT function as revealed by our microarray
analysis and inhibition of p53 site-specific acetylation.
Furthermore, these molecules also hold tremendous
therapeutic potential for different diseases including
AIDS and cancer.
EXPERIMENTAL PROCEDURES
General Procedure for the Synthesis and Characterization
of Derivatives
See the Supplemental Data.
Histone Acetyltransferase Assay
HAT assays were performed as described previously [6]. 1.8 mg of
highly purified HeLa core histones were incubated in HAT assay buffer
at 30C for 10 min with or without baculovirus-expressed recombinant
p300 or PCAF in the presence and absence of IG derivatives followed
by addition of 0.5 ml of 4.7 Ci/mmol [3H] acetyl CoA (NEN-PerkinElmer)
and were further incubated for another 10 min in a 30 ml reaction. The
reaction mixture was then blotted onto P-81 filter paper (Whatman),
and radioactive counts were recorded on a PerkinElmer Wallac 1409
liquid scintillation counter. The radio labeled acetylated histones
were visualized by resolving on 15% SDS-polyacrylamide gel and
subjected to fluorography followed by autoradiography.
Surface-Enhanced Raman Spectroscopy
Raman spectroscopic studies were carried out on a custom built
Raman spectrometer described elsewhere [27]. The laser excitation
used was 532 nm from a frequency doubled diode pumped Nd-YAG
laser with a maximum power of 8 mW at the sample. The typical
accumulation times for each spectrumwere 180 s. The silver nanopar-
ticles were prepared by the standard Lee and Meisel method as
described earlier [27]. The typical size of the Ag nanoparticles were
found to be 50 nm by transmission electron microscopy. p300Chemistry & Biology 14, 6solution (protein concentration40 ng/ml) wasmixed with Ag nanopar-
ticles solution in the ratio of 1:4 and put on to a cavity glass slide. The
mixture was allowed to settle for 5 min before recording the SERS with
a water immersion high-magnification objective. To record the p300
spectrum with the inhibitors, a 10 mM solution of IG or its derivative
was added to the above mixture.
In Vitro Chromatin Transcription
Chromatin template for in vitro transcription was assembled and char-
acterized as described earlier [6]. Transcription assays were carried
out as described earlier [6] with minor modifications. The scheme of
transcription is shown in Figure 5A. The experiment is carried out in
the presence and absence of 50 mM Garcinol, IG, and LTK-14, and
all the steps were followed as described earlier [22].
Analysis of In Vivo Histone Acetylation
HeLa cells (1.53 106 cells per 60mmdish) were seeded overnight, and
histones were extracted from 24 hr of compound-treated cells. The
quantitated protein samples were run on a 12% SDS-polyacrylamide
gel. After electrophoresis, proteins on the gel were electrotransferred
onto an Immobilon membrane (polyvinylidene difluoride; Millipore,
Corp., Bedford, MA). The membranes were then blocked in 5% nonfat
dry milk solution in 13 PBS containing 0.05% Tween 20 and then im-
munoblotted with anti-acetyl H3, or anti-H3. Detection was performed
with goat anti-rabbit secondary antibody (BangaloreGenei), and bands
were visualized with the use of the ECL detection system (Pierce).
Immunofluroscence
To visualize the inhibition of histone acetylation in vivo, HeLa cells were
cultured as monolayer on the poly L-lysine-coated cover slips in
DMEM (Sigma) medium. Immunofluroscence was carried out as de-
scribed elsewhere [44]. Fixed cells were probed with antiacetylated
histone H3 polyclonal antibodies followed by secondary antibodies
conjugated with Alexa 488. To stain the chromosomal DNA Hoechst
33528 (Sigma) was used. The images were taken by using Zeiss
LSM 510 laser scanning confocal microscope.
p53 Modulation Assays
In vitro p53 acetylation assays were carried out either with p300 or
PCAF similarly as HAT assays described above. Flag-tagged p53
was incubated for 10min in the presence and absence of LTK-14 either
with p300 or PCAF. Then 0.5 ml of 4.7 Ci/mmol [3H] acetyl CoA (NEN-
PerkinElmer) was added and incubated further for 30 min at 30C.
Then reaction mixtures were subjected to fluorography followed by
autoradiography. For in vivo p53 modulation studies, A549 cells were
incubated for 24 hr with LTK-14 (100 mM) and DMSO. Cells were then
treated with 0.5 mg/ml of doxorubicin for 6 and 12 hr. The cells were
harvested and lysed by using TNN buffer (150 mM NaCl, 50 mM Tris
[pH 7.4], 1% Nonidet P-40, 0.1% sodium deoxycholate, 1 mM EDTA,
0.5 mg/ml leupeptin, 0.5 mg/ml aprotinin, and 0.5 mg/ml pepstatin), for
3 hr on ice with intermittent mixing. The whole-cell lysates from the
above treatments were subjected to western analysis by using mouse
monoclonal anti-p53 antibody, DO1 (oncogene), rabbit polyclonal
acetylated p53 K373 and K320 (Upstate), and actin (Calbiochem).
Microarray Analysis
The total RNA was isolated from control and treated cells by using
the TRIZOL (Invitrogen) method. The Micromax direct labeling kit,
MPS502 (PerkinElmer), was used to synthesize the labeled cDNA
from 70 mg of total RNA and further process the hybridized cDNA on
the array. All the steps were carried out according to manufacturer’s
instructions (http://las.perkinelmer.com/content/Manuals/MAN_Micro
maxDirect50Reactions25Arrays.pdf). The array slides were scanned
immediately with a PerkinElmer ScanArray Gx microarray scanner.
The ScanArray software (PerkinElmer) was used for grid-wise normal-
ization of array images. Four arrays were used with at least two biolog-
ical treatments of cells, and dye-swap experiments were included in
the final analysis. The data were analyzed by GeneSpring GX and45–657, June 2007 ª2007 Elsevier Ltd All rights reserved 655
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p300-Specific HAT InhibitorBiointerpreter softwares from Genotypic Technology, Bangalore. The
differential expression was considered if the Log2 mean of at least 1
for the downregulated genes and +1 for the upregulated genes.
We considered only the genes that were reproducible from all four
replicates.
Real-Time PCR Analysis
cDNA was synthesized from total RNA by using oligo (dT) and
SuperScript real-time PCR kit (Invitrogen). The real-time generated
cDNA was amplified with gene-specific primers (Sigma-Aldrich),
ATF-6 (forward primer 50-gactctttcacaggctggatg-30, reverse primer
50-cttccttcagtggctccgc-30 ), PLIN (forward primer- 50-gagaatgtgctg
cagcggg-30, reverse primer- 50-gcgggtggagatggtgtc-30), and iQ
SYBRGreen Supermix (BioRad). Actin was used as an internal control.
PCR analysis was performed with a BioRad iCycler real-time PCR
machine.
Syncytium Inhibition Assay and p24 Estimation
The cell lines SupT1 and H9/HTLV-IIIb NIH 1983 were obtained from
the NIH AIDS Research and Reference Reagent Program. H9/HTLV-
IIIb NIH 1983 cells carrying stably integrated proviruses were cocul-
tured with excess numbers of SupT1 cells at a ratio of 1:200. A total
of 1 3 106 cells were seeded in each well of a 24-well plate and
cultured in RPMI medium supplemented with 10% fetal calf serum
and antibiotics. LTK-14 in DMSO was added to the cells at a range
of concentration, and the cultures were incubated at 37C. All the
wells, including the control, received the same amount of DMSO.
Formation of syncytia was visible under light microscope within
12 hr. The total number of syncytia in ten representative wells was
counted at different time points (24, 48, and 72 hr); data for the 48 hr
time point are presented. Identical results were obtained at other
time points. Culture supernatant was sampled every 24 hr for p24 anal-
ysis. Empigen was added to each sample to a final concentration of
0.1%, and the samples were incubated at 56C for 30min to inactivate
the virus and to release the p24 antigen. The quantity of p24 in the
samples was measured with a commercial kit following manufac-
turer’s instructions (PerkinElmer, Boston, MA). All the assays were
performed in triplicate wells, and the experiment was performed two
times.
Supplemental Data
Supplemental Data include the Supplemental Experimental Proce-
dures and results of (1) histone deacetylase and methyltransferase
assays, (2) expression and purification of proteins, (3) cytotoxic assay,
and (4) isolation of garcinol, synthesis of garcinol derivatives, and
characterization and X-ray structure determination of LTK-14 and
are available at http://www.chembiol.com/cgi/content/full/14/6/645/
DC1/.
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